Starpharma granted fast track approval for VivaGel

Company News

by Jessica Amir

Starpharma Holdings Limited, (ASX:SPL) says the FDA has granted a fast track designation as well as a Qualified Infectious Disease Product designation, for its VivaGel product.

VivaGel is used for the treatment and prevention of bacterial vaginoisis in women.

Starpharma has estimated that the market relating to the treatment and prevention of this infection is worth in excess of US$1 billion.

The company says it’s a very positive commercial development which expedites the path to US market entry for VivaGel.

Starpharma posted a net loss of $22.7 million at 30 June 2016.
 

Jessica Amir

Finance News Network
Jessica is a senior finance journalist and presents the Market Outlook, Market at Midday and Market Wrap. She also presents ASX company news and interviews CEOs. She joined FNN in January 2017 with six years of broadcast journalism experience. She worked as a journalist and producer with Sky News Business, ABC 1, ABC's The Business and ABC24. She also worked in regional Australia for Prime 7 and WIN News as a TV reporter. In her prior life she worked as a financial planner.